WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a life sciences company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will participate in a virtual cardiology congress via CardiocareLive produced by PlatformQ. The interactive webcast will feature Pieter Muntendam, MD, President and CEO of BG Medicine, who will provide an overview of the role of galectin-3 in the development and progression of heart failure. Dr. Muntendam has led the research and development efforts to identify the role of galectin-3 in cardiac disease from its original preclinical studies through its current clinical use in the FDA-cleared BGM Galectin-3TM test for use in patients with heart failure. The title of the webcast is “Finding the Disease in Heart Failure – Role of Galectin-3 in Heart Failure Development and Progression.” The webcast will be held on Thursday, December 8, 2011, at 11 a.m. Eastern Time.
